Adenocor

Each 10 ml vial contains 30 mg adenosine (3 mg/ml).

ADENOSCAN 30 MG / 10 ML SOLUTION FOR INFUSION

Coronary vasodilator to be used in conjunction with radiodiagnostic myocardial perfusion techniques in those patients who are unable to perform adequate exercise or for whom exercise is contraindicated.

Reserved for hospital use where cardiac monitoring and cardio-respiratory resuscitation equipment are available for immediate use, if necessary. It should be administered where cardiac monitoring and cardio-respiratory resuscitation equipment is available as well as stress testing.Continuous electrocardiogrphic control is necessary during administration as life-threatening arrhythmia may occur. Heart rate and blood pressure should be monitored every minute. Adults: administer undiluted as a continuous peripheral intravenous infusion at a dose of 140 mcg / kg / min for six minutes using an infusion pump. It is recommended not to use the same venous site for the administration of the drug and radionuclide, Soto avoid a bolus effect of adenosine. To ensure a sufficient time to the appearance of the peak in the coronary blood flow inject the radionuclide after three minutes of infusion. Optimal vasodilation is achieved after six minutes of infusion. To avoid a bolus effect of adenosine, measure the pressure in the arm opposite to that of the infusion. Determine undiluted infusion rate in relation to body weight (total dose 0.84 mg / kg).. Paediatric population: the safety and efficacy of adenosine in children aged between 0 and 18 years have not been established. No dosage recommendation can be made. Elderly: as for adults

Contraindicated in patients with hypersensitivity to the active substance or to any of the excipients, atrioventricular(AV) block second or third degree, sick sinus syndrome (except of the patients with pacemaker functioning, long QT syndrome, severe ipot dimension, unstable angina not stabilized properly terapiamedica, heart failure is not compensated, lung disease cro nica obstructive pulmonary disease with evidence of bronchospasm (e.g. bronchial asthma),concomitant use of dipyridamole.

The effects related to the pharmacological activity of adenosine are frequent, but are generally reduced spontaneously and are short-lived. If the effect is not tolerable, discontinue the infusion. Methylxanthines such as intravenous aminophylline or theophylline have been used to end persistent side effects (50-125 mg per slow intravenous injection). Adverse events are classified by frequency: very common (>=1/10), common (>=1/100, =1/1000, =1/10000,